Long-term survival in a dog with primary hepatic neuroendocrine tumor treated with toceranib phosphate.

Masanao Ichimata, Shinichiro Nishiyama, Fukiko Matsuyama, Eri Fukazawa, Kei Harada, Ryuzo Katayama, Atsushi Toshima, Yumiko Kagawa, Tetsushi Yamagami, Tetsuya Kobayashi

The Journal of veterinary medical science 2021 Oct 05

filter terms:

Primary hepatic neuroendocrine tumors (PHNETs) are rare in dogs, and limited information exists about the treatment of these tumors. A 12-year-old castrated male French bulldog was presented to our clinic with gastrointestinal signs. Diagnostic tests revealed increased hepatic enzyme levels, a mass in the hepatic quadrate lobe, multiple intrahepatic nodules, and enlarged hepatic hilar lymph nodes. The liver mass was diagnosed cytologically as a malignant epithelial tumor suspected to be of neuroendocrine origin. The dog was treated with single-agent toceranib phosphate (TOC) and survived 25.1 months after the initial presentation. On necropsy, a liver mass was found and was subsequently diagnosed as a PHNET on histopathology. To the best of our knowledge, this is the first report of long-term survival in a dog with PHNET treated with TOC.

Citation

Masanao Ichimata, Shinichiro Nishiyama, Fukiko Matsuyama, Eri Fukazawa, Kei Harada, Ryuzo Katayama, Atsushi Toshima, Yumiko Kagawa, Tetsushi Yamagami, Tetsuya Kobayashi. Long-term survival in a dog with primary hepatic neuroendocrine tumor treated with toceranib phosphate. The Journal of veterinary medical science. 2021 Oct 05;83(10):1554-1558